Conceivably, critically-ill non-septic patients who have persistent elevation of lymphocyte PD-1 expression and who are at high risk of infection might be candidates for therapy with anti-PD-1 antibodies to boost their immunity and prevent or ameliorate these infections. The gene discussed is PDCD1; the disease is infection.